Recent Updates
Recently added Catalysts
MDGL Positive Sentiment

Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026

Wednesday, June 3, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Madrigal Pharmaceuticals will participate in the 47th Annual Global Goldman Sachs Health Care Conference on June 10, 2026. The event will feature a live webcast of the presentation, which will be accessible through their Investor Relations page. Madrigal's lead product, Rezdiffra, is approved for treating MASH, and a Phase 3 trial is ongoing for compensated MASH cirrhosis.
Price reaction · baseline $452.86 (2026-06-02 close) · hit after-hours · 1 other MDGL headline(s) in the window, move may be shared
day 0 close
+7.8%
day 1 · peak
+8.8%
day 3
+3.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Madrigal Pharmaceuticals is participating in a prominent healthcare conference.
  • The company is focused on addressing a significant medical need with its therapies.
  • Rezdiffra has received FDA and European Commission approval for MASH treatment.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+125%
120-day peak, hindsight
Typical move
4.2%
average across 7 past catalysts
Cash runway
~45 mo
Minimal dilution risk
Lead asset
Resmetirom
Phase 3 · Non-Alcoholic Fatty Liver Disease

Full Press Release Details

CONSHOHOCKEN, Pa., June 03, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the 47thAnnual Global Goldman Sachs Health Care Conference 2026 on Wednesday, June 10, 2026, at 11:20 A.M. EDT.
The presentation will be webcast live and may be accessedhereor by visiting Madrigal’s Investor Relations Events and Presentationspage. A replay of the webcast will be available after the event.
About MadrigalMadrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra was the first medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visitwww.madrigalpharma.comand follow uson LinkedIn.

Investor ContactTina Ventura,IR@madrigalpharma.com

Media ContactChristopher Frates,media@madrigalpharma.com

Frequently Asked Questions

When is Madrigal Pharmaceuticals participating in the conference?

Madrigal Pharmaceuticals will participate on June 10, 2026, at 11:20 A.M. EDT.

How can I access the conference presentation?

The presentation will be webcast live and accessible via Madrigal's Investor Relations page.

What is Rezdiffra used for?

Rezdiffra is approved for treating metabolic dysfunction-associated steatohepatitis (MASH).

Is there a replay available for the conference?

Yes, a replay of the webcast will be available after the event.

ShareAdd on Google
Tags: MDGL Viatris Investor Conferences Healthcare Madrigal Pharmaceuticals Goldman Sachs Rezdiffra MASH
Last updated: Jun 3, 2026

Biotech snapshot

Cash runway
$839M liquidity · $19M/mo burn
~45 mo
Minimal dilution risk
Lead asset
ResmetiromPhase 3
Non-Alcoholic Fatty Liver Disease →

Catalyst track record

+125%
best trade around MDGL's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for MDGL.

See every catalyst's timing & PoA →